[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]

Gan To Kagaku Ryoho. 1991 Jan;18(1):115-8.
[Article in Japanese]

Abstract

An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA. Complete response was obtained both against liver and lymph node metastases from 7 months after the initial treatment. A mild bone marrow suppression and appetite loss were observed as the side effect. It is suggested that the combination therapy may be useful for previously treated patients with advanced breast cancer.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / pathology
  • Adenocarcinoma / secondary*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Etoposide / administration & dosage
  • Female
  • Floxuridine / administration & dosage
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Lymphatic Metastasis
  • Medroxyprogesterone / administration & dosage
  • Medroxyprogesterone / analogs & derivatives
  • Medroxyprogesterone Acetate
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage
  • Remission Induction

Substances

  • Mitomycins
  • Floxuridine
  • Mitomycin
  • Etoposide
  • Medroxyprogesterone Acetate
  • Medroxyprogesterone
  • doxifluridine